The Lu Xiangyi blood type card centrifuge is used for the detection of neonatal hemolytic disease.
Release time:
2016-11-17
Overview:
TD4G Blood Type Card Centrifuge This is a new multi-purpose centrifuge introduced by our company, which incorporates advanced foreign technologies and has been further improved to suit the domestic industry. The machine is primarily used for blood typing and serological tests, routine blood examinations, microcolumn gel assays, and immunological testing.
1. Neonatal Hemolytic Disease
1.1 Hemolytic disease of the newborn (HDN) is a self-limiting, immune-mediated syndrome associated with hemolysis that occurs during the fetal period and in the early neonatal period. It can lead to premature birth, miscarriage, stillbirth, neonatal kernicterus, intellectual disability, and even disability or death. Among these, ABO HDN has the highest incidence among newborns with blood type incompatibility in China. According to available literature, ABO HDN accounts for 85.3% of all cases of HDN, and among these cases, 93.9% involve mothers with blood type "O." Theoretically, in pregnant women with blood types "A" or "B," HDN may occur whenever the husband's blood type is neither the same as the mother's nor "O."
1.2 ABO HDN occurs when there is an ABO blood type incompatibility between the pregnant woman and the fetus. Under certain circumstances, fetal red blood cells enter the maternal circulation, stimulating the mother’s body to produce IgG antibodies. These immune antibodies can cross the placenta and enter the fetal circulation, where they destroy the fetal red blood cells. This condition primarily affects pregnancies in which the mother has blood type “O” and the fetus has blood type “A” or “B.” The clinical symptoms of ABO HDN include edema, jaundice, hepatosplenomegaly, anemia, and kernicterus. There is a close relationship between the detection of prepartum serum IgG antibody titers in “O”-type pregnant women and the occurrence of HDN; the higher the antibody titer, the greater the likelihood of HDN. For pregnant women whose partners have incompatible ABO blood types, it is advisable to routinely perform antibody testing during pregnancy and, if necessary, adopt active therapeutic measures to reduce the maternal serum IgG antibody levels.
Blood Type Card Centrifuge
Blood Type Card Centrifuge 2-Micropillar Gel Immunodetection Technology
2.1 Microcolumn agglutination (MCA) is a newly emerging serological technique for blood typing that was developed and clinically applied abroad in the 1990s. It has been introduced to China only within the past three to four years. However, due to its numerous methodological advantages, it has already been widely adopted for pre-transfusion serological antibody screening. The principle behind this technique involves preparing a gel of a specific concentration using a diluent that meets the requirements for serological testing and then filling microcolumn tubes with this gel. The spaces between the gel particles act as molecular sieves: under certain centrifugal conditions, pores of an appropriate size allow only single red blood cells to pass through, while agglutinated red blood cells or sensitized red blood cells (which can react with anti-globulin reagents in the diluent) are unable to pass through, thus providing a clear distinction among different agglutination results. Agglutinated red blood cells float on top of the gel or disperse throughout the gel, indicating a positive reaction; non-agglutinated red blood cells settle at the bottom of the gel, yielding a negative result. The microcolumn gel anti-globulin test (MGCT) builds upon this principle by incorporating anti-globulin reagents into the gel, thereby achieving sensitivity comparable to both direct and indirect antiglobulin tests used in conventional anti-globulin methods and enabling the detection of IgG-class antibodies.
2.2 Detection of IgG Anti-A(B) Antibody Titer in Pregnant Women: The traditional testing method is the antiglobulin test (Coombs’ test), which holds great clinical significance. However, due to factors such as the need for repeated red blood cell washing during the procedure and the requirement for sensitized red cells to confirm negative results, this test’s clinical application has been significantly limited. The microcolumn gel antiglobulin test is an emerging testing method that offers several advantages: it is simple, rapid, time- and labor-saving, yields results that are easier to interpret, provides stable reaction outcomes, is easy to store, and allows photographic documentation of the test results for long-term preservation. The principle behind the microcolumn gel antiglobulin test is that red blood cells sensitized by maternal IgG antibodies bind to the antiglobulin reagent within the microcolumns, causing agglutination. These sensitized red blood cells cannot pass through the gaps between the gel particles, and after centrifugation, they fail to reach the bottom of the microcolumns. In contrast, red blood cells not sensitized by maternal IgG antibodies do not bind to the antiglobulin reagent in the microcolumns; thus, after centrifugation, these cells pass through the gel particle gaps and reach the bottom of the microcolumns. Moreover, since only red blood cells come into contact with the antiglobulin reagent during centrifugation—while free serum remains separate—there is no need to repeatedly wash the red blood cells, and the incubation time is greatly reduced to just 15 minutes. Compared with the conventional method, this significantly simplifies the operational steps and shortens the incubation period. Therefore, the microcolumn gel antiglobulin test is a simple, rapid, sensitive, and accurate testing method.
2.3 With the continuous development and improvement of clinical blood transfusion techniques and the growing awareness of maternal and neonatal health care, the demand for related clinical tests has been steadily increasing. As our understanding of hemolytic disease of the newborn (HDN) caused by maternal-fetal blood group incompatibility deepens, prenatal screening to determine whether the couple’s blood types are compatible and whether the pregnant woman carries IgG antibodies has become increasingly effective in making a clear diagnosis during pregnancy. By monitoring the pregnancy to estimate the severity of fetal disease and promptly implementing appropriate therapeutic measures, as well as determining the optimal timing for delivery, we can play a crucial role in preventing the occurrence of HDN.
Shanghai Luxiangyi Centrifuge Instrument Co., Ltd. pays close attention to the development of the medical industry, introduces advanced foreign technologies, and designs and improves medical centrifuges specifically tailored to China’s domestic medical conditions, thereby supporting the needs and development of China’s medical sector.